- Home
- CHRS vs EDF Comparison
CHRS vs EDF Comparison
Compare CHRS & EDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | EDF |
|---|---|---|
| Founded | 2010 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 153.0M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHRS | EDF |
|---|---|---|
| Price | $2.01 | $5.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.51 | N/A |
| AVG Volume (30 Days) | ★ 3.3M | 160.6K |
| Earning Date | 03-09-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $277,728,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $79.66 | N/A |
| P/E Ratio | $1.53 | ★ N/A |
| Revenue Growth | ★ 152.07 | N/A |
| 52 Week Low | $0.71 | $3.51 |
| 52 Week High | $2.62 | $5.50 |
Technical Indicators
Market Signals| Indicator | CHRS | EDF |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 59.94 |
| Support Level | $1.97 | $4.98 |
| Resistance Level | $2.20 | $5.04 |
| Average True Range (ATR) | 0.23 | 0.05 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 8.39 | 69.23 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.